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Data miningTo inform an understanding of brain status in HIV infection, quantitative imagingmeasurements were derived at
structural, microstructural and macromolecular levels in three different periods of early infection and then ana-
lyzed simultaneously at each stage using data mining. Support vectormachine recursive feature elimination was
then used for simultaneous analysis of subject characteristics, clinical and behavioral variables, and immunologic
measures in plasma and CSF to rank features associated with the most discriminating brain alterations in each
period. The results indicate alterations beginning in initial infection and in all periods studied. The severity of
immunosuppression in the initial virus host interaction was the most highly ranked determinant of earliest
brain alterations. These results shed light on the initial brain changes induced by a neurotropic virus and their
subsequent evolution. The pattern of ongoing alterations occurring during and beyond the period in which
virus is suppressed in the systemic circulation supports the brain as a viral reservoir that may preclude eradica-
tion in the host. Data mining capabilities that can address high dimensionality and simultaneous analysis of dis-
parate information sources have considerable utility for identifyingmechanisms underlying onset of neurological
injury and for informing new therapeutic targets.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Injury to the brain is a serious complication of Human Immunodeﬁ-
ciency Virus (HIV). Early viral invasion of the brain is evidenced by virus
in cerebrospinal ﬂuid within only 7–10 days of transmission (Valcour,
2012a). Subsequent changes, however, are not well characterized
because the infection often remains undiagnosed in the earliest stages.
Additionally, to evaluate the brain in subclinical periods requires quan-
titative imagingwhich is not routinely available. This investigation used
Magnetic Resonance (MR) imaging to examine the brain at structural,
microstructural and macromolecular levels in three different periods
of the early clinical course: Primary Infection, 4–12 months post-
infection (pi) and N12–24 months pi. Duration of infection was
determined by antibody non-reactivity (for Primary Infection) and
assay values from a recent infection testing algorithm (Keating, 2012).
Volumetric measurements were derived from high resolution neuroan-
atomic images for the major tissue classes with SIENAX (Smith, 2002)
and for approximately ﬁfty individual brain regions with Freesurfer1 312 926 5991.
pi.edu (X. Kong),
ic.edu (P. Yu),
. This is an open access article under(Fischl, 2002). Diffusion Tensor Imaging (DTI) parameters, fractional
anisotropy (FA) andmean diffusivity (MD), were used to quantifymicro-
structural alterations at levels approximating cellular dimensions (Basser
and Pierpaoli, 1996a). Magnetization Transfer Ratio (MTR) was used to
quantify macromolecular changes (e.g. in lipids, membranes, myelin)
(Wolff and Balaban, 1994). DTI and MT parameters (FA, MD and MTR)
were calculated for 3D volumes of interest, including cerebral cortex, ce-
rebral white matter, corpus callosum, caudate, putamen, thalamus and
hippocampus. Dataminingmethodswere used to analyzemeasurements
from the multiple MRI sequences simultaneously in order to determine
the most discriminating brain measures (features) in each period of HIV
infection compared to normative values fromagematched seronegative
controls. Recursive feature selection was also used to determine factors
most highly associated with a composite measure of the brain alter-
ations identiﬁed in each period. This analysis considered subject charac-
teristics, clinical laboratorymeasures (e.g. HIV RNA and complete blood
count), medical history information, behavioral measures (e.g. alcohol/
substance use), and immunologic measures in plasma and CSF.
2. Materials and methods
Northwestern University Institutional Review Board approved this
investigation, which was conducted in compliance with U.S. federalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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included 56HIV (50males, 6 females;mean age: 33.3±10.1 years) and
21 seronegative control (16 males, 5 females; mean age: 31.4 ±
8.9 years) subjects. Study exclusion criteria included chronic neurolog-
ical disorder, head injury, uncontrolled seizure disorder, experimental
drugs or vaccinationwithin the past 15 days, radiation or chemotherapy
within prior month, mental condition involving inability to understand,
chronic alcohol or drug abuse, pregnancy, opportunistic infection, can-
cer, medical condition (heart, liver or kidney) or MR contraindication.
None of the participants had history of Kaposi3s sarcoma, primary CNS
lymphoma, non-CNS lymphoma or prior radiation therapy. Demo-
graphic and clinical information is presented in Table 1. HIV and sero-
negative groups did not differ in age, gender, racial composition or
education level. Marijuana use was reported by more participants in
the HIV than control group.
Blood samples were collected from all subjects; CSF was acquired
from consenting HIV subjects (n= 11). HIV serostatus was determined
by enzyme-linked immunosorbent assay andWestern blot. An early in-
fection assay (EIA) was used to assess duration of infection (Blood Sys-
tems Research Institute, San Francisco, CA). Antibody non-reactivity
was used to deﬁne Primary Infection (estimated as less than
4 months pi; n = 15); 4–12 months pi (n = 15; EIA: 7.65–35.5), in-
fected N12–24 months (n = 26; EIA N35.5). For the HIV group, abso-
lute CD4 T cell counts ranged from 139 to 1282 cells/µL (mean:
546 ± 254.0 cells/µL); plasma viral load (log10) ranged from unde-
tectable to 5.54 copies/mL (mean: 3.34 ± 1.5 copies/mL). Plasma
viral loadwas undetectable (b50 copies/mL) in 11 of the 56HIV subjects,
including 10 suppressed on antiretroviral therapy (ART) (0–4months pi:
n = 2; 4–12 months pi: n = 2, N12–24 months pi: n = 6). Thirty of
the HIV subjects were ART naïve and 26 had initiated treatment
with subgroup distribution as follows: (0–4 months pi: 7 naïve, 8 ART),
(4–12 months pi: 11 naïve, 4 ART) and (N12–24 months pi: 12 naïve;
14 ART).2.1. Cytokine/chemokine quantiﬁcation
Multiplex analyses were conducted at Blood Systems Research
Institute (San Francisco). Plasma/CSF was aliquoted locally, frozen and
shipped for long-term storage and for batched analysis. The high-
sensitivity MilliPlex kit (Millipore) was used for IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12 p70, IL-13, IFN-γ, GM-CSF and TNF-α. The
standard-sensitivity Milliplex Map kit (Millipore) was used for epider-
mal growth factor (EGF), Eotaxin, ﬁbroblast growth factor (FGF)-2,
Fractalkine, IL-1α, IL-1Rα, IL-9, IL-12(p40), IL-15, IL-17, IP-10,monocyte
chemotactic protein (MCP)-1, MCP-3, macrophage-derived chemokine
(MDC), macrophage inﬂammatory protein (MIP)-1α, MIP-1β, sIL-2Rα,
TNFβ, and vascular endothelial growth factor (VEGF). The MMP panelTable 1
Demographic characteristics.
HIV (n = 56) Control (n = 21) p
Age (mean years ± SD) 33.3 ± 10.1 31.4 ± 8.9 0.45
Gender (% male) 89% 76% 0.22
Race (% White) 62% 76% 0.22
Education (% college) 81% 90% 0.29
Substance use (past month)
Alcohol (5 or more drinks) 7 4 0.51
Marijuana 20 3 0.04
Cocaine 3 0 0.08
Amphetamines 2 0 0.39
Glue or solvent snifﬁng 0 0 –
Heroin 0 0 –
Other 3 0 0.082 was used for MMP-1, MMP-2, MMP-7, MMP-9, MMP-10 and a
singleplex was used for SDF-1. Manufacturer's protocols were followed.
Serum was incubated overnight with antibody-coupled beads followed
by incubation with biotinylated detection antibody, and ﬁnally, incuba-
tionwith streptavidin-PE. Each samplewas assayed in duplicate and cy-
tokine standards, and controls, supplied by the manufacturer, were run
on each plate. In addition, manufacturer controls and in-house controls
consisting of supernatants of PBMCs stimulatedwithmitogen in culture
are also run. Multi-analyte proﬁling was performed using a Luminex-
100 system and data were analyzed using BioPlex 6.1 software
(BioPlex). Luminex Standard Curve: A 5-PL curve ﬁt is used to graph
the 7-point standard curve. The curve for every analyte was checked
for the ﬁt of the standard data points. If there were errors or more
than a 30% CV for any standard, those points were dropped. The curve
ﬁt parameterwas altered if necessary dependingon the number of stan-
dard points.
2.2. Flow cytometry
Whole blood was collected into ethylenediaminetetraacetic acid
(EDTA) anticoagulant and assayedwithin 24 h. Sampleswere processed
using a simple lyse-wash-stain-wash technique. For a given sample, six-
teen 5-mL polystyrene tubes were each ﬁlled with 100 µL of whole
blood (seven tubes for seven marker panels, one unstained tube, and
eight for compensation control). To lyse red blood cells, 2 mL of
freshly-prepared 1× NH4Cl solution was added to each tube and incu-
bated for 10 min at room temperature. Cells were then spun down by
centrifuge at 1500 rpm for 6 min at 4 °C, washed twice with 2 mL
PBS + 2% BSA, and resuspended in 50 µL of PBS + 2% BSA solution for
blocking. Antibodies were added to corresponding tubes and incubated
in the dark at 4 °C for 45 min. Cells were removed from incubation,
washed again twice with PBS + 2% BSA, and resuspended in PBS con-
taining 0.5% formaldehyde. Cell populations were gated on a minimum
of 250,000 cells and sorted on basis of 99% purity. Samples were ac-
quired initially on Cyan ADP (Beckman Coulter, Inc.) and later on BD
LSRFortessa ﬂow cytometers (Beckton, Dickinson and Company).
Logarithmic ampliﬁer linearity and dynamic range were tested with
Rainbow beads (Spherotech, Libertyville, IL). Compensation matrix
was created using single-color compensation controls to correct for
any spectral overlap/spillover. Compensation settings were adjusted
using singly-stained peripheral blood samples. Sample analysis was
done using FlowJo (Treestar, Inc., Ashland, OR).
2.3. MR imaging
Imaging data were acquired on a single MR scanner, a 3 T
MAGNETOM Tim Trio (Siemens, Erlangen, Germany) with maxi-
mum gradient slew rate, 200 mT/m/s, maximum gradient strength,
40 mT/m, using a 12 channel receive-only head coil. Sagittal whole
brain Magnetization Prepared Rapid Acquisition Gradient Echo images
were acquired [parameters: TR/TI/TE: 2300/900/2.91 ms; ﬂip angle:
9°; ﬁeld of view: 256 × 256 mm; slice thickness: 1 mm; resolution:
1mm× 1mm; slices: 176]. For DTI, a 2D double refocused spin echo se-
quence with echo planar readout was used for acquisition [parameters:
Axial, TR/TE: 9700/90 ms, ﬂip-angle: 90°, ﬁeld of view: 256 × 256 mm,
in-plane resolution: 2 × 2 mm, slice thickness: 2 mm, slices: 72,
bandwidth: 1326 Hz/Px, averages: 1, acceleration factor: 2, directions:
64, b = [0; 1000] s/mm2]. High-resolution MT was acquired using a
3D MT-weighted fast spoiled gradient echo (GRE) pulse sequence
with the following parameters: TR = 43 ms, TE = 5 ms, ﬂip angle 10°,
and 144 1.0-mm slices scanned for axial plane. The scanning matrix
was 256 × 256 with a ﬁeld of view of 256 mm, resulting in a voxel
size of 1.0 × 1.0 × 1.0 mm3. To decrease scan time while maintaining
resolution, receiver bandwidth was 200 Hz/pixel and an 81.3%
rectangular ﬁeld of view was used.
Fig. 1. SVM-RFE algorithm.
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For all MR modalities, image quality control was performed visually
by a trained operator to ensure that artifacts were not present. Image
analysis was blinded to group status (HIV or control). SIENAX (Oxford
University, Oxford, England) was used to calculate volumetric measure-
ments for brain parenchyma, ventricular and tissues classes (gray
matter, cortical graymatter, whitematter, and cerebrospinal ﬂuid), nor-
malized for differences in head size. Smith (2002) SIENAX ﬁrst extracts
a brain and skull image from the subject’s structural MPRAGE input
image. The skull image is used to determine registration scaling from
subject space to standard space (MNI125). This scaling is then used in
the afﬁne-registration of the brain image to standard space. This process
deﬁnes the volumetric scaling factor used to normalize brain volume. To
avoid introducing error from blurring associated with registration,
tissue segmentation is performed on the original (non-registered)
MPRAGE images and volumes are then scaled by the scaling factor to de-
rive the normalized measurements. Freesurfer, Fischl (2002) was used
to derive measurements of individual brain regions. To minimize oper-
ator variability in manual editing, a semi-automated approach was
used. Image quality was assessed based on case by case visual inspec-
tion; skull stripping and segmentation results met quality assurance
standards for both cortical and subcortical segmentation. To adjust for
differences in head size, Freesurfer measurements for individual brain
regionswere divided by the intracranial cavity volume. DTI parameters,
including fractional anisotropy (FA), which is sensitive to white matter
integrity, and mean diffusivity (MD), which quantiﬁes water molecular
diffusion at levels approximating cellular dimensions, were determined
for aggregate 3D volumes of interest. Volumes of interest included re-
gions that have been identiﬁed as vulnerable to injury in studies of
more advanced infection HIV infection, including cerebral cortex, cere-
bral white matter, corpus callosum, caudate, putamen, thalamus and
hippocampus (Tate, 2011; Anthony and Bell, 2008; Becker, 2011;
Chiang, 2007; Cohen, 2010; Thompson, 2012; Thompson, 2006; Wu,
2008; Wu, 2006; Wohlschlaeger, 2009). Parametric FA and MD maps
were derived using custom software on a Linux workstation. Eddy-
current-induced distortions were corrected in the SE-EPI-DTI images
by registering all diffusion-weighted images to the B0 image for
each slice. DTI and MTR parametric maps were coregistered to the
anatomical T1 structural image using FLIRT (FMRIB3s Linear Registra-
tion Tool). For DTI, the B0 image was used to calculate a transforma-
tion matrix between DTI and T1, which was then applied back to the
DTI images to align them. For MTR, the mt0 (no saturation pulse)
image was used to calculate a transformation matrix between MTR
and T1. Fractional anisotropy (FA) and mean diffusivity (MD) were
then calculated using standard equations for all voxels within 3D vol-
umes of interest (Basser and Pierpaoli, 1996b). This approach was also
used to calculate MTR for 3D volumes based on (M0 − MS) / M0,
where MS and M0 are the signal intensities with and without the MT
saturation pulse.
3. Results
Classiﬁcation problems were formulated on each HIV subgroup:
0–4 months (n = 15), 4–12 months (n = 15) and N12–24 months
post-infection (n = 26) vs. controls (n = 21). To determine the dis-
criminative brain measures for the HIV subgroups vs. controls, brain
measurements from segmentation, Freesurfer, DTI and MT were
used as feature vectors x, with class label y = 1 if the subject was
included in the subgroup, y =−1 otherwise.
Recursive feature elimination (RFE) based on Support Vector Ma-
chines (SVMs) (Guyon et al., 2002; Cao et al., 2014) was implemented.
Support Vector Machines (SVMs) learn a weight for each feature in
the training process, similar to linear or logistic regression. The differ-
ence is that instead of minimizing the square error or the logit loss,
SVMs choose the weight vector to maximize the geometric marginbetween two classes of samples. Support Vector Machines Recursive
Feature Elimination (SVM-RFE) uses the weight magnitude as the
ranking criterion. The SVM-RFE algorithm is a well-established and ef-
fective wrapper-based feature selection method, which is a backward
sequential selection method that removes one feature at a time. SVM-
RFE has four general steps: (1) train an SVM on the training set,
(2) order features using the weights of the resulting classiﬁer, (3) elim-
inate features with the smallest weight, and (4) repeat the process with
the training set restricted to the remaining features. In this algorithm,
the SVM classiﬁer is used to evaluate the discriminative power of the
selected subset of features.
min
w;b;ξ
1
2
wk k22 þ c∑
n
i¼1
ξi
s:t:yiw
Txi þ b ≥1 ξi
ξi ≥ 0;∀i ¼ 1;⋯;n;
where w can be regarded as the weight vector of the separating
hyperplane in the feature product space, b is the bias, ξi is the error of
the ith training instance, and c is the trade-off between the margin
and empirical loss. It can be solved with use of optimization techniques
developed for SVMs, and the weight vectorw can be obtained from
w ¼∑
n
i¼1
αiyixi
where αi is the dual variable corresponding to each instance.
The objective of SVM-RFE is to ﬁnd the subset of features that opti-
mizes the performance of the SVMclassiﬁer. The algorithmwas adapted
as recording the sequence of removing features, in order to return a
complete ranked list of features. The later a feature is removed, the
more discriminating it is. The algorithm is summarized in Fig. 1. A linear
kernel based SVM classiﬁer based on the LIBSVM librarywas adopted in
the current framework (Chang and Lin, 2011, 2014).
Table 2 presents classiﬁcation performance between control andHIV
groups at different stages of infection, using the ﬁve and ten highest
ranked features, as selected by the SVM-RFE algorithm, and using all
brain measures without feature selection. Using all brain measures
without feature selection fails to optimize classiﬁcation because the
original feature set may contain potentially redundant and irrelevant
features. Training a classiﬁer on these features, especially with a limited
number of available subjects, as in these data, can result in overﬁtting
Table 2
Classiﬁcation performance.
Brain measures Accuracy Sensitivity (recall) Speciﬁcity Precision F1
0–4 months pi
10 highest ranked 0.917 ± 0.28 0.958 ± 0.14 1.000 ± 0.00 1.000 ± 0.00 0.972 ± 0.09
5 highest ranked 0.833 ± 0.38 0.917 ± 0.19 1.000 ± 0.00 1.000 ± 0.00 0.944 ± 0.13
All 0.722 ± 0.45 0.931 ± 0.18 0.931 ± 0.18 0.931 ± 0.18 0.907 ± 0.15
4–12 months pi
10 highest ranked 0.889 ± 0.32 0.972 ± 0.12 0.972 ± 0.12 0.972 ± 0.12 0.963 ± 0.11
5 highest ranked 0.667 ± 0.48 0.861 ± 0.23 0.972 ± 0.12 0.972 ± 0.12 0.889 ± 0.16
All 0.583 ± 0.50 0.903 ± 0.20 0.889 ± 0.21 0.889 ± 0.21 0.861 ± 0.17
N12–24 months pi
10 highest Ranked 0.809 ± 0.40 0.936 ± 0.17 0.968 ± 0.12 0.968 ± 0.12 0.936 ± 0.13
5 highest Ranked 0.596 ± 0.50 0.894 ± 0.21 0.904 ± 0.20 0.904 ± 0.20 0.865 ± 0.17
All 0.426 ± 0.50 0.840 ± 0.24 0.872 ± 0.22 0.872 ± 0.22 0.809 ± 0.17
Averages ± standard deviations of evaluation metrics based on leave one out cross validation. pi: post-infection.
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data. Therefore, selecting discriminative features is critical to build a
robust classiﬁer. On the other hand, classiﬁcation performance with
only the ﬁvemost discriminating brainmeasures is not optimal because
ﬁve features may not be informative enough to learn an effective
classiﬁer. Our constructed classiﬁer using the ten highest ranked
features, presented in Table 3, achieved the best classiﬁcation, as
shown by various widely used performance metrics (Table 2).
A similar approach was then used to identify features most closely
associated with the discriminating brain measures at each stage
(Table 3). For this analysis, the most discriminating brain measures
were considered as continuous labels and the RFE algorithmwas imple-
mented on other features by replacing SVMs with Support Vector Re-
gression Machines (SVRs) (Drucker, et al., 1997). SVRs were trained
independently for the top k (default: k= 10) discriminative brainmea-Table 3
Most discriminative brain measurements by stage (highest rank: top).
Brain measurement HIV mean ± S
0–4 months post-infection
Cortical gray matter volume 6.7244e+05 ±
DTI FA: mid-posterior CC 5.9215e−01 ±
3rd ventricle volume 6.4700e−04 ±
Lateral ventricle volume 6.7434e−03 ±
Brainstem volume 1.4313e−02 ±
DTI FA: anterior CC 6.4761e−01 ±
DTI MD: aggregate white matter 7.2813e−04 ±
Cerebral cortex volume 3.1773e−01 ±
DTI FA: corpus callosum 6.6370e−01 ±
Gray matter volume 8.8307e+05 ±
4–12 months post-infection
DTI FA: corpus callosum 6.6062e−01 ±
DTI FA: cerebral white matter 4.4810e−01 ±
Caudate volume 5.1246e−03 ±
4th ventricle volume 1.0509e−03 ±
DTI FA: anterior CC 6.5497e−01 ±
DTI FA: hippocampus 1.7001e−01 ±
White matter volume 6.9372e+05 ±
MTR: hippocampus 3.5146e+01 ±
Posterior CC volume 5.8357e−04 ±
Amygdala volume 2.4801e−03 ±
Over 12–24 months post-infection
Cerebral cortex volume 3.1552e−01 ±
DTI FA: corpus callosum 6.6903e−01 ±
DTI FA: hippocampus 1.6806e−01 ±
Cortical gray matter volume 6.8367e+05 ±
DTI MD: hippocampus 9.3385e−04 ±
MTR: central CC 4.3771e+01 ±
DTI FA: whole brain 2.8722e−01 ±
Caudate volume 4.8686e−03 ±
Inferior lateral ventricle vol. 3.3846e−04 ±
DTI MD: anterior CC 9.0638e−04 ±sures. For each SVR, there is a ranking criterion cðiÞ ¼ wTðiÞwðiÞ; i ¼ 1…k,
whichwere combined via summation, c ¼∑ki¼1cðiÞ. The ﬁnal predictors
were determined by removing, in sequence, the feature with the
smallest c value in each iteration — the later a feature is removed, the
more discriminating the feature. Table 4 presents rankings for the
predictors.4. Conclusions
To inform an understanding of the onset of HIV-induced changes,
this study examined the brain at structural, microstructural (Diffusion
Tensor) andmacromolecular (Magnetization Transfer) levels in individ-
uals infected less than 4 months (antibody nonreactive, Primary HIV),
4–12 months post-infection (pi) and in early chronic infection, deﬁnedD Control mean ± SD
6.8826e+04 7.1210e+05 ± 3.4820e+04
7.8661e−02 6.3608e−01 ± 3.8864e−02
1.2523e−04 5.5920e−04 ± 1.1147e−04
2.6941e−03 8.6943e−03 ± 3.7096e−03
8.3209e−04 1.3477e−02 ± 9.6935e−04
5.2708e−02 6.9982e−01 ± 5.5296e−02
2.1672e−05 7.3381e−04 ± 1.3945e−05
3.4012e−02 3.3188e−01 ± 1.8838e−02
3.9193e−02 6.9255e−01 ± 2.2936e−02
7.7013e+04 9.2598e+05 ± 5.4841e+04
4.3113e−02 6.9255e−01 ± 2.2936e−02
1.4325e−02 4.6036e−01 ± 1.4384e−02
6.7222e−04 4.7463e−03 ± 4.7151e−04
2.4087e−04 1.3410e−03 ± 4.2966e−04
3.0413e−02 6.9982e−01 ± 5.5296e−02
8.8006e−03 1.6015e−01 ± 1.3612e−02
2.2541e+04 6.8139e+05 ± 4.1380e+04
1.1827e+00 3.4391e+01 ± 2.3965e+00
1.3621e−04 6.1219e−04 ± 7.4019e−05
3.1429e−04 2.3440e−03 ± 1.4224e−04
2.3740e−02 3.3188e−01 ± 1.8838e−02
4.4107e−02 6.9255e−01 ± 2.2936e−02
2.0701e−02 1.6015e−01 ± 1.3612e−02
4.4681e+04 7.1210e+05 ± 3.4820e+04
3.5553e−05 9.4498e−04 ± 3.6070e−05
2.6509e+00 4.4982e+01 ± 2.4494e+00
1.0762e−02 2.8599e−01 ± 9.9421e−03
4.5856e−04 4.7463e−03 ± 4.7151e−04
1.5106e−04 2.7575e−04 ± 1.2414e−04
1.2362e−04 8.9962e−04 ± 1.1957e−04
Table 4
Ranked determinants of brain alterations (highest: top).
0–4 months post-infection
CBC: CD4+/CD8+
Flow: CD8+ T cells
Luminex: TNFα
CSF: GM-CSF
CBC: absolute basophils
Luminex: IL-6
Flow: %CD36+, T cells
Flow: %CD45RO+, CD16+ monocytes
CBC: hematocrit
Luminex: MMP-7
Luminex: fractalkine
Luminex: MMP-1
Flow: %CD3−CD56+CD16−, NK cells
Flow: %CD36+, CD33+ monocytes
CBC: absolute CD4+
Luminex: MCP-1
4–12 months post-infection
CBC: %CD3+, total lymphocytes
Flow: %B cells, total lymphocytes
Flow: %CD36+, CD33+ monocytes
Luminex: MMP-1
Alcohol use frequency, past month
Flow: %CD4+,CD3+CD56+CD16− NKT cells
Flow: % singlets, lymphocytes
Flow: %T Cells, total lymphocytes
Flow: %CD56+, CD16−monocytes
CBC: monocytes percent
Luminex: IL-9
Length of infection
Substance use: marijuana, past 6 months
Flow: %CD45RO+, CD16+ monocytes
Over 12–24 months post-infection
Age
Flow: %CD3−CD56+CD16+, NK cells
Flow: %CD36+, CD33+ monocytes
Luminex: MMP-1
Flow: %CD4+,CD3+CD56−CD16+ NKT cells
Luminex: TNFα
CBC: eosinophils percent
Emtricitabine exposure (an NRTI)
Luminex: MDC
Luminex: MMP-10
Luminex: IL-4
Flow: %CD4−CD8−,CD3−CD56+CD16− NK cells
Flow: %CD71+, CD33+ monocytes
Luminex: MIP-1β
Fig. 2. Group differences of most discriminating brain measures. Group differences for
highest ranked brain measures at each stage: 0–4 months (cortical gray matter volume),
4–12 months (corpus callosum DTI FA) and N12–24 months (cerebral cortex volume)
post-infection. HIV groups were compared with controls using t-tests. FA (fractional
anisotropy).
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in Primary Infection involved graymatter, white matter and ventricular
measurements (Table 3). Cortical Gray Matter Volume was highest
ranked, with reduced levels compared to controls (Fig. 2). Examination
of the means for other highly ranked features presented in Table 3 sug-
gests a similar pattern for volumetric measurements of cerebral cortex
and graymatterwith enlargement of brainstem, third and lateral ventri-
cles. Findings for microstructural measurements (DTI) are consistent
with diffusion restriction in white matter. Three of the most highly
ranked features in Primary Infection involved anisotropymeasurements
of corpus callosum (Fig. 2).
Alterations quantiﬁed in Primary Infection likely reﬂect acute neuro-
inﬂammation following initial viral invasion of the brain. The blood
brain barrier generally shelters neural tissue frompotential toxins, how-
ever, permeability may be altered in immune perturbances of the initial
viral host interaction (McMichael, 2010; Borrow and Bhardwaj, 2008;
Stacey, 2009). Consistent with very early brain involvement, virus can
be detected in the cerebrospinal ﬂuid in Acute HIV and the initial symp-
tom presentation includes headache (Valcour, 2012b). Abnormalities in
gray matter and ventricular expansion are apparent on clinical MR in
patients with Acute HIV meningoencephalitis (Yoshizawa et al., 2007).An autopsy only 15 days following an iatrogenic infection revealed neu-
ropathological ﬁndings in meninges, cortex and subcortical regions
(Davis, 1992).
The brain was also examined in the period immediately following
the adaptive immune response (4–12 months pi). This is an immuno-
logically signiﬁcant period in which viral and immune activation set
points become established (Mellors, 1996; Deeks, 2004). Evidence
that ART within the ﬁrst year confers greater beneﬁt (e.g. Le, 2013;
Burdo, 2011) motivated investigation of the immediately subsequent
period: N12–24 months pi. Highly ranked features at 4–12 months
reveal a prominent pattern of subcortical ﬁndings and involvement of
cerebral white matter (Table 3). Anisotropy measurements of corpus
callosum were highest ranked in this period (Table 3; Fig. 2). Other
callosal and white matter measures were also highly ranked. Examina-
tion of the means in Table 3 suggests ﬁndings consistent with swelling
in this period immediately following seroconversion, in aggregate
brain white matter, caudate and amygdala. Hippocampal involvement,
which has been reported at autopsy (Anthony and Bell, 2008) was
quantiﬁed with two separate modalities (FA and MTR). The pattern ob-
served N12–24 months pi was consistent with both prior periods
(Table 3). Cortical and cortical gray matter volume were reduced with
microstructural anisotropy alterations in corpus callosum (Fig. 2).
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lateral) and ongoing involvement of caudate, hippocampus and
individual callosal segments.
The dramatic immune perturbances characteristic of the initial virus
host interaction are generally followed by a prolonged asymptomatic
period in association with host defense (McMichael, 2010; Schacker,
1996). In the brain, however, earliest alterations do not appear to
resolve with seroconversion. Alterations in corpus callosum and in the
anterior callosal segment were identiﬁed in all studied periods. Alter-
ations in caudate, considered a predilection site of viral injury and in
hippocampus were quantiﬁed in the period immediately following
seroconversion (4–12 months) and persisted thereafter. Brain alter-
ations evident over 12 months pi were consistent with ongoing neuro-
inﬂammation, loss of white matter integrity and atrophy.
This analysis also used data mining to identify the factors associated
with brain alterations observed in each period. This analysis considered
subject characteristics, medical history, clinical laboratory measures,
lymphocyte and other immune cell subsets, cytokines, chemokines
and behavioral measures (e.g. alcohol/substance use). The factors
most closely associated with the earliest alterations in the brain includ-
ed critical markers of immunologic status — plasma CD4+/CD8+ ratio
and CD8+ T cells (Table 4). Other factors associated with brain
alterations in primary infection (0–4 months pi) included: TNFα, baso-
phils, IL-6, hematocrit, CD36+ T Cells, CD16+CD45RO+ monocytes,
MMPs (−7 and −1), fractalkine, CD3−CD56+CD16− NK cells,
CD33+CD36+ monocytes, MCP-1, as well as CD4+ T cells. GM-CSF,
which stimulatesmonocyte/granulocyte expansion,was highest ranked
in CSF. The ﬁnding for basophils (mast cell precursors) suggests
potential mast cell mediated meningeal inﬂammation (Ransohoff and
Brown, 2012). Factors most highly associated with brain alterations at
4–12 months pi included plasma MMP-1, IL-9, populations of circulat-
ing monocytes, as well as infection duration, alcohol and marijuana
use. Age, which has been established as a risk factor for HIV
neurocognitive impairment (e.g. Valcour, 2004), was highest ranked
in those infected more than 12 months. Age ranked higher than all
other factors identiﬁed in this period, which included plasma MMP-1,
TNFα, eosinophils, emtricitabine exposure, CD33+CD36+ monocytes,
total CD3−CD56+CD16+ NK cells, MDC, MMP-10, IL-4, CD3−
CD56+CD16− (%CD4−CD8−) NK cells, CD33+CD71+ monocytes,
and MIP-1β.
These ﬁndings clarify evidence implicating a legacy event involving
severe immunosuppression in cognitive deterioration (Valcour, 2006;
Ellis et al., 2010, 2011). Onset of neural injury may date to massive
CD4+ loss and severe immunosuppression that occurs in Primary infec-
tion. Viremia reaches staggering peak levels within only 21–28 days pi
(Gasper-Smith, 2008). Uncontrolled viremia in the initial virus host in-
teraction is accompanied bymassive loss of CD4+T cells and a cytokine
storm.HIV subverts immune control/host defense by infecting cells crit-
ical to pathogen response— CD4+ T cells and monocyte/macrophages,
which serve as a vehicle for brain ingress, facilitated by immune activa-
tion, MMPs and cytokines/chemokines, such as TNFα, IL-6 (similarly,
hematocrit), fractalkine and MCP-1 (Gartner and Liu, 2002; MacLean,
2004). Infected macrophages in the meninges (Lamers, 2011), sub-
arachnoid space and parenchyma induce inﬂammatory cascades
(Lindl, 2010) involving cytokines, chemokines and other immune
mediators which disturb neuronal and glial function (Kaul and Lipton,
2006). Neurons may be injured from exposure to viral proteins, as
well as immune-stimulated macrophages/microglia (Kaul, 2009). The
brain has a limited repertoire for responding to insult and injury.
Microglia and astrocytes, which do not have direct counterparts in the
periphery, are the primary mediators of these responses in the brain
(Ransohoff and Brown, 2012). The viral protein, tat, for example,
increases intracellular calcium, potentiates excitotoxicity, and induces
apoptosis (Eugenin, 2007; Haughey, 2001). Transient exposure to viral
proteins may cause progressive neuropathological changes for days
(Nath, 1999).Of markers in plasma, MMP-1 was highly ranked in all periods stud-
ied.MMPs are potent proteolytic enzymes that when dysregulated pose
serious risk of tissue destruction (Sternlicht and Werb, 2001). MMPs
have been implicated in HIV associated brain injury (Suryadevara,
2003; Dhar, 2006). MMP-1 may modulate the neurotoxicity of HIV
viral proteins (Conant, 2004; Rumbaugh, 2006). Additionally, prolonged
astrocyte activation may result in elevated MMP-1 levels (Suryadevara,
2003). Circulating MMP-1 levels correlate with the severity of brain
injury in advanced infection (e.g. Ragin, 2009). CD33+CD36+
monocytes, which were also identiﬁed in all three periods, have been
implicated in impaired ingestion of damaged cells and pathogen, dys-
regulated lipid metabolism, atherosclerosis, and cardiovascular disease
(Olivetta, 2014; Feeney, 2013). CD16+CD45RO+ monocytes, a subset
of activated monocytes, were highly ranked speciﬁcally within the
ﬁrst year of infection, consistent with ﬁndings from brain autopsy
(Cosenza-Nashat, 2006). The ﬁrst year of infection may also be time-
critical for optimizing preservation of immune function (Le, 2013)
and potentially for preserving the brain. Treatment status was not
identiﬁed as a highly ranked feature of the most discriminating
brain alterations, other than the ﬁnding for Emtricitabine exposure,
which was identiﬁed N12–24 months pi. This study, however, is
based on an observational cohort in which timing and duration of
antiretroviral therapy varied in individual participants and the per-
centage of naïve and ART participants differed in the HIV subgroups.
Findings of early brain involvement underscore the importance of
further studies clarifying whether ART in initial infection confers
neuroprotective beneﬁt.
When interpreting these ﬁndings, it is important to appreciate that
microstructural (DTI) and macromolecular (MTR) parameters were
only measured in select regions— early brain involvement may extend
to regions not interrogated here. Additionally, brain alterations
observed in early infection may also reﬂect neuroreparative efforts
(e.g. neurogenesis, hippocampus) changes (Kaul, 2009). Alterations in
only a single period (e.g. brainstem, amygdala) may reﬂect short-lived
or evolving changes (e.g. localized neuroinﬂammation), transient
changes in surrounding brain regions, or pseudonormalization. If het-
erogeneous changes are occurring within a given structure (e.g. swell-
ing and atrophic changes), this may yield “pseudonormal” measures
that underestimate early brain involvement. Nevertheless, the consis-
tent pattern observed in three different samples across three different
time periods support the premise of onset of brain alterations in early
HIV infection. Moreover, other studies have found brain changes early
in HIV infection (Valcour, 2012b; Peluso, 2013; Spudich, 2011; Ances,
2009; Wang, 2011) reporting similar ﬁndings, such as altered neuronal
integrity in frontal cortexwithmicroglial activation in basal ganglia and
an association with circulating monocytes across the ﬁrst year of infec-
tion (e.g. Lentz, 2011).
These ﬁndings shed light on brain changes induced by HIV and their
evolution in initial stages of infection. The severity of immunosuppres-
sion in the initial virus host interaction, possibly mediated by host fac-
tors associated with immune compromise (e.g. alcohol, substance use,
age), may determine the relative degree of early brain involvement.
While transient, uncontrolled viremia and immunosuppression in Pri-
mary Infection may have lasting effects on the brain. The brain alter-
ations detected in early infection mirror the atrophy, striatal and
callosal injury, seen in advanced HIV infection (e.g. Becker, 2011;
Thompson, 2006; Thompson, 2005) and at autopsy (Wohlschlaeger,
2009). Early changes, for example, in the cerebral cortex, may also be
broadly relevant to the abnormalities that have been identiﬁed at vari-
ous levels in advanced HIV infection, such as patterns of gray matter
loss and aberrant function in localized cortical areas shownbymagneto-
encephalography (Becker, 2012a,b, 2013; Wilson, 2013a,b, 2015), as
well as alterations in brain resting state functional connectivity shown
by fMRI (Thomas, 2013).
Similarly, many of the factors associatedwith the earliest brain alter-
ations, such as markers of immune activation and of circulating
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(Ragin, 2009; Sevigny, 2004, 2007; Ragin, 2010, 2011; Gartner, 2000).
This analysis identiﬁed abnormalities in caudate and hippocampus
within only 4–12 months pi. Early onset of neural injury may explain
why atrophy e.g. in basal ganglia, corresponds with duration of infec-
tion, despite successful viral suppression by ART (Becker, 2011). Early
onset of neural injury may explain why treatment may fail to confer
neuroprotection (Brew, 2007). Evidence of ongoing brain alterations
across the period in which systemic viral suppression occurs supports
the premise that a viral reservoir is established in the brain very early
in infection, that may preclude viral eradication in the host. Treatment
in acute infection may confer greater neuroprotective beneﬁt by sup-
pressing the intensity of initial viremia, thereby preserving CD4+ T
cells and immune function while potentially limiting early seeding of
the brain and other reservoirs. Alterations involving the corpus
callosum and in the anterior callosal segment were identiﬁed in all pe-
riods, suggesting that measures in this region may represent promising
biomarkers of early brain involvement in HIV infection with potential
utility for quantifying effects of intervention.Acknowledgments
This work was supported by the National Institute of Mental Health
(R01-MH080636). The authors appreciate the services of the Center for
Translational Imaging. All authors state they have no conﬂict of interests
related to this manuscript.References
Ances, B.M., et al., 2009. Resting cerebral blood ﬂow: a potential biomarker of the effects
of HIV in the brain. Neurology 73 (9), 702–708. http://dx.doi.org/10.1212/WNL.
0b013e3181b59a9719720977.
Anthony, I.C., Bell, J.E., 2008. The neuropathology of HIV/AIDS. Int. Rev. Psychiatry 20 (1),
15–24. http://dx.doi.org/10.1080/0954026070186203718240059.
Basser, P.J., Pierpaoli, C., 1996a. Microstructural and physiological features of tissues
elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. B 111 (3),
209–219. http://dx.doi.org/10.1006/jmrb.1996.00868661285.
Basser, P.J., Pierpaoli, C., 1996b. Microstructural and physiological features of tissues
elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. B 111 (3),
209–219. http://dx.doi.org/10.1006/jmrb.1996.00868661285.
Becker, J.T., et al., 2011. Subcortical brain atrophy persists even in HAART-regulated HIV
disease. Brain Imaging Behav. 5 (2), 77–85. http://dx.doi.org/10.1007/s11682-011-
9113-821264551.
Becker, J.T., et al., 2012a. Potential utility of resting-state magnetoencephalography as a
biomarker of CNS abnormality in HIV disease. J. Neurosci. Methods 206 (2),
176–182. http://dx.doi.org/10.1016/j.jneumeth.2012.02.02222414786.
Becker, J.T., et al., 2012b. Functional connectivity measured with magnetoencephalogra-
phy identiﬁes persons with HIV disease. Brain Imaging Behav. 6 (3), 366–373.
http://dx.doi.org/10.1007/s11682-012-9149-422328062.
Becker, K.M., et al., 2013. Decreased MEG beta oscillations in HIV-infected older adults
during the resting state. J. Neurovirol. 19 (6), 586–594. http://dx.doi.org/10.1007/
s13365-013-0220-824297500.
Borrow, P., Bhardwaj, N., 2008. Innate immune responses in primary HIV-1 infec-
tion. Curr. Opin. H.I.V. A.I.D.S. 3 (1), 36–44. http://dx.doi.org/10.1097/COH.
0b013e3282f2bce719372942.
Brew, B.J., 2007. Lost in translation: again, another failed neuroprotection trial. Neurol. 69
(13), 1308–1309. http://dx.doi.org/10.1212/01.wnl.0000277530.05450.ff17893290.
Burdo, T.H., et al., 2011. Soluble CD163 made by monocyte/macrophages is a novel mark-
er of HIV activity in early and chronic infection prior to and after anti-retroviral ther-
apy. J. Infect. Dis. 204 (1), 154–163. http://dx.doi.org/10.1093/infdis/jir21421628670.
Cao, B., et al., 2014. Tensor-based multi-view feature selection with applications to brain
diseases. IEEE International Conference on Data Mining, Shenzhen, China.
Chang, C.-C., Lin, C.-J., 2011. LIBSVM: a library for support vector machines. A.C.M. Trans-
actions Intell. Syst. Technol. 2 (3), 1–27. http://dx.doi.org/10.1145/1961189.1961199.
Chang, C.-C., Lin, C.-J., 2014. LIBSVM: A Library for Support Vector Machines. [Software]
[cited 2015 January 1] available from: http://www.csie.ntu.edu.tw/~cjlin/libsvm/.
Chiang, M.C., et al., 2007. 3D pattern of brain atrophy in HIV/AIDS visualized using
tensor-based morphometry. Neuroimage 34 (1), 44–60. http://dx.doi.org/10.
1016/j.neuroimage.2006.08.03017035049.
Cohen, R.A., et al., 2010. Effects of nadir CD4 count and duration of human immunodeﬁcien-
cy virus infection on brain volumes in the highly active antiretroviral therapy era.
J. Neurovirol. 16 (1), 25–32. http://dx.doi.org/10.3109/1355028090355242020113183.
Conant, K., et al., 2004. Matrix metalloproteinase 1 interacts with neuronal integrins and
stimulates dephosphorylation of Akt. J. Biol. Chem. 279 (9), 8056–8062. http://dx.doi.
org/10.1074/jbc.M30705120014679206.Cosenza-Nashat, M.A., et al., 2006. CD45 isoform expression inmicroglia and inﬂammato-
ry cells in HIV-1 encephalitis. Brain Pathol. 16 (4), 256–265. http://dx.doi.org/10.
1111/j.1750-3639.2006.00027.x17107594.
Davis, L.E., et al., 1992. Early viral brain invasion in iatrogenic human immunodeﬁciency
virus infection. Neurol. 42 (9), 1736–1739. http://dx.doi.org/10.1212/WNL.42.9.
17361513462.
Deeks, S.G., et al., 2004. Immune activation set point during early HIV infection predicts
subsequent CD4+ T-cell changes independent of viral load. Blood 104 (4),
942–947. http://dx.doi.org/10.1182/blood-2003-09-333315117761.
Dhar, A., et al., 2006. Novel role of TGF-beta in differential astrocyte-TIMP-1 regulation:
implications for HIV-1-dementia and neuroinﬂammation. J. Neurosci. Res. 83 (7),
1271–1280. http://dx.doi.org/10.1002/jnr.2078716496359.
Drucker, H., et al., 1997. Support vector regressionmachines. Advances in Neural Informa-
tion Processing Systems 9, 155–161.
Ellis, R., Heaton, R., Letendre, S., Badiee, J., Munoz-Moreno, J., Vaida, F., Cliffford, D.,
Gelman, B., Simpson, D., Grant, I., Charter Group, 2010. Higher CD4 nadir is associated
with reduced rates of HIV-associated neurocognitive disorders in the CHARTER
study: potential implications for early treatment initiation. Conference on Retrovi-
ruses and Opportunistic Infections, San Francisco, CA.
Ellis, R.J., et al., 2011. CD4 nadir is a predictor of HIV neurocognitive impairment in the era
of combination antiretroviral therapy. A.I.D.S. 25 (14), 1747–1751. http://dx.doi.org/
10.1097/QAD.0b013e32834a40cd21750419.
Eugenin, E.A., et al., 2007. HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS
complex that promotes apoptosis in neurons and astrocytes. Proc. Natl. Acad. Sci. U.
S. A. 104 (9), 3438–3443. http://dx.doi.org/10.1073/pnas.061169910417360663.
Feeney, E.R., et al., 2013. The expression of cholesterol metabolism genes in monocytes
from HIV-infected subjects suggests intracellular cholesterol accumulation. J. Infect.
Dis. 207 (4), 628–637. http://dx.doi.org/10.1093/infdis/jis72323204179.
Fischl, B., et al., 2002. Whole brain segmentation: automated labeling of neuroanatomical
structures in the human brain. Neuron 33 (3), 341–355. http://dx.doi.org/10.1016/
S0896-6273(02)00569-X11832223.
Gartner, S., 2000. HIV infection and dementia. Science 287 (5453), 602–60410691542.
Gartner, S., Liu, Y., 2002. Insights into the role of immune activation in HIV
neuropathogenesis. J. Neurovirol. 8 (2), 69–75. http://dx.doi.org/10.1080/
1355028029004952511935459.
Gasper-Smith, N., et al., 2008. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma
microparticles after human immunodeﬁciency virus type 1 (HIV-1) transmission:
implications for HIV-1 vaccine design. J. Virol. 82 (15), 7700–7710. http://dx.doi.
org/10.1128/JVI.00605-0818508902.
Guyon, I., et al., 2002. Gene selection for cancer classiﬁcation using support vector
machines. Mach. Learn. 46 (1–3), 389–422.
Haughey, N.J., et al., 2001. HIV-1 Tat through phosphorylation of NMDA receptors poten-
tiates glutamate excitotoxicity. J. Neurochem. 78 (3), 457–467. http://dx.doi.org/10.
1046/j.1471-4159.2001.00396.x11483648.
Kaul, M., 2009. HIV-1 associated dementia: update on pathological mechanisms and
therapeutic approaches. Curr. Opin. Neurol. 22 (3), 315–320. http://dx.doi.org/10.
1097/WCO.0b013e328329cf3c19300249.
Kaul, M., Lipton, S.A., 2006. Mechanisms of neuroimmunity and neurodegeneration
associated with HIV-1 infection and AIDS. J. Neuroimmune Pharmacol. 1 (2),
138–151. http://dx.doi.org/10.1007/s11481-006-9011-918040780.
Keating, S.M., et al., 2012. Lower-sensitivity and avidity modiﬁcations of the VITROS anti-
HIV 1 + 2 assay for detection of recent HIV infections and incidence estimation.
J. Clin. Microbiol. 50 (12), 3968–3976. http://dx.doi.org/10.1128/JCM.01454-
1223035182.
Lamers, S.L., et al., 2011. HIV-1 phylogenetic analysis shows HIV-1 transits through the
meninges to brain and peripheral tissues. Infect. Genet. Evol. 11 (1), 31–37. http://
dx.doi.org/10.1016/j.meegid.2010.10.01621055482.
Le, T., et al., 2013. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.
N. Engl. J. Med. 368 (3), 218–230. http://dx.doi.org/10.1056/NEJMoa111018723323898.
Lentz, M.R., et al., 2011. Alterations in brain metabolism during the ﬁrst year of HIV infec-
tion. J. Neurovirol. 17 (3), 220–229. http://dx.doi.org/10.1007/s13365-011-0030-
921494901.
Lindl, K.A., et al., 2010. HIV-associated neurocognitive disorder: pathogenesis and thera-
peutic opportunities. J. Neuroimmune Pharmacol. 5 (3), 294–309. http://dx.doi.org/
10.1007/s11481-010-9205-z20396973.
MacLean, A.G., et al., 2004. Activation of the blood–brain barrier by SIV (simian immuno-
deﬁciency virus) requires cell-associated virus and is not restricted to endothelial
cell activation. Biochem. Soc. Trans. 32 (5), 750–752. http://dx.doi.org/10.1042/
BST0320750.
McMichael, A.J., et al., 2010. The immune response during acute HIV-1 infection: clues for
vaccine development. Nat. Rev. Immunol. 10 (1), 11–23. http://dx.doi.org/10.1038/
nri267420010788.
Mellors, J.W., et al., 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in
plasma. [erratum in: science 1997 January 3; 275(5296):14]. Science 272 (5265),
1167–1170. http://dx.doi.org/10.1126/science.272.5265.11678638160.
Nath, A., et al., 1999. Transient exposure to HIV-1 Tat protein results in cytokine
production in macrophages and astrocytes: a hit and run phenomenon.
J. Biol. Chem. 274 (24), 17098–17102. http://dx.doi.org/10.1074/jbc.274.24.
1709810358063.
Olivetta, E., et al., 2014. HIV-1 Nef impairs key functional activities in humanmacrophages
through CD36 downregulation. PLOS One 9 (4), e93699. http://dx.doi.org/10.1371/
journal.pone.009369924705461.
Peluso, M.J., et al., 2013. Cerebrospinal ﬂuid and neuroimaging biomarker abnormal-
ities suggest early neurological injury in a subset of individuals during primary
HIV infection. J. Infect. Dis. 207 (11), 1703–1712. http://dx.doi.org/10.1093/
infdis/jit08823460748.
82 B. Cao et al. / NeuroImage: Clinical 9 (2015) 75–82Ragin, A.B., et al., 2009. Serummatrix metalloproteinase levels correlate with brain injury
in human immunodeﬁciency virus infection. J. Neurovirol. 15 (3), 275–281. http://dx.
doi.org/10.1080/1355028090291327119444696.
Ragin, A.B., et al., 2010. Biomarkers of neurological status in HIV infection: a 3-year
study. Proteomics Clin. Appl. 4 (3), 295–303. http://dx.doi.org/10.1002/prca.
20090008321137050.
Ragin, A.B., et al., 2011. Marked relationship between matrix metalloproteinase 7 and
brain atrophy in HIV infection. J. Neurovirol. 17 (2), 153–158. http://dx.doi.org/10.
1007/s13365-011-0018-521302026.
Ransohoff, R.M., Brown,M.A., 2012. Innate immunity in the central nervous system. J. Clin.
Invest. 122 (4), 1164–1171. http://dx.doi.org/10.1172/JCI5864422466658.
Rumbaugh, J., et al., 2006. Interaction of HIV Tat and matrix metalloproteinase in HIV
neuropathogenesis: a new host defense mechanism. F.A.S.E.B. J. 20 (10),
1736–1738. http://dx.doi.org/10.1096/fj.05-5619fje16807369.
Schacker, T., et al., 1996. Clinical and epidemiologic features of primary HIV
infection.[see comment][erratum appears in Ann intern Med 1997 January 15;
126(2):174]. Ann. Intern. Med. 125 (4), 257–264. http://dx.doi.org/10.7326/
0003-4819-125-4-199608150-000018678387.
Sevigny, J.J., et al., 2004. Evaluation of HIV RNA and markers of immune activation as pre-
dictors of HIV-associated dementia. Neurol. 63 (11), 2084–2090. http://dx.doi.org/10.
1212/01.WNL.0000145763.68284.1515596754.
Sevigny, J.J., et al., 2007. An evaluation of neurocognitive status and markers of immune
activation as predictors of time to death in advanced HIV infection. Arch. Neurol. 64
(1), 97–102. http://dx.doi.org/10.1001/archneur.64.1.9717210815.
Smith, S.M., et al., 2002. Accurate, robust, and automated longitudinal and cross-sectional
brain change analysis. Neuroimage 17 (1), 479–489. http://dx.doi.org/10.1006/nimg.
2002.104012482100.
Spudich, S., et al., 2011. Central nervous system immune activation characterizes primary
human immunodeﬁciency virus 1 infection even in participants with minimal cere-
brospinal ﬂuid viral burden. J. Infect. Dis. 204 (5), 753–760. http://dx.doi.org/10.
1093/infdis/jir38721844301.
Stacey, A.R., et al., 2009. Induction of a striking systemic cytokine cascade prior to
peak viremia in acute human immunodeﬁciency virus type 1 infection, in con-
trast to more modest and delayed responses in acute hepatitis B and C virus
infections. J. Virol. 83 (8), 3719–3733. http://dx.doi.org/10.1128/JVI.01844-
0819176632.
Sternlicht, M.D., Werb, Z., 2001. How matrix metalloproteinases regulate cell behavior.
Annu. Rev. Cell Dev. Biol. 17, 463–516. http://dx.doi.org/10.1146/annurev.cellbio.17.
1.46311687497.
Suryadevara, R., et al., 2003. Regulation of tissue inhibitor ofmetalloproteinase-1 by astro-
cytes: links to HIV-1 dementia. Glia 44 (1), 47–56. http://dx.doi.org/10.1002/glia.
1026612951656.
Tate, D.F., et al., 2011. Regional areas and widths of the midsagittal corpus callosum
among HIV-infected patients on stable antiretroviral therapies. J. Neurovirol. 17 (4),
368–379. http://dx.doi.org/10.1007/s13365-011-0033-621556960.
Thomas, J.B., et al., 2013. Pathways to neurodegeneration: effects of HIV and aging on
resting-state functional connectivity. Neurology 80 (13), 1186–1193. http://dx.doi.
org/10.1212/WNL.0b013e318288792b23446675.
Thompson, M.A., et al., 2012. Antiretroviral treatment of adult HIV infection: 2012 recom-
mendations of the International Antiviral Society-USA panel. JAMA 308 (4), 387–402.
http://dx.doi.org/10.1001/jama.2012.796122820792.Thompson, P.M., et al., 2005. Thinning of the cerebral cortex visualized in HIV/AIDS
reﬂects CD4+ T lymphocyte decline. Proc. Natl. Acad. Sci. U. S. A. 102 (43),
15647–15652. http://dx.doi.org/10.1073/pnas.050254810216227428.
Thompson, P.M., et al., 2006. 3D mapping of ventricular and corpus callosum abnormali-
ties in HIV/AIDS. Neuroimage 31 (1), 12–23. http://dx.doi.org/10.1016/j.neuroimage.
2005.11.04316427319.
Valcour, V., et al., 2004. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii
aging with HIV cohort. J. Neuroimmunol. 157 (1–2), 197–202. http://dx.doi.org/10.
1016/j.jneuroim.2004.08.02915579298.
Valcour, V., et al., 2006. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of
current cognitive and neurological status in human immunodeﬁciency virus type 1
infection — the Hawaii aging with HIV cohort. J. Neurovirol. 12 (5), 387–391.
http://dx.doi.org/10.1080/1355028060091533917065131.
Valcour, V., et al., 2012a. Central nervous system viral invasion and inﬂammation during
acute HIV infection. J. Infect. Dis. 206 (2), 275–282. http://dx.doi.org/10.1093/infdis/
jis32622551810.
Valcour, V., et al., 2012b. Central nervous system viral invasion and inﬂammation during
acute HIV infection. J. Infect. Dis. 206 (2), 275–282. http://dx.doi.org/10.1093/infdis/
jis32622551810.
Wang, X., et al., 2011. Abnormalities in resting-state functional connectivity in early
human immunodeﬁciency virus infection. Brain Connect. 1 (3), 207–217. http://dx.
doi.org/10.1089/brain.2011.001622433049.
Wilson, T.W., et al., 2013a. Abnormal MEG oscillatory activity during visual processing in
the prefrontal cortices and frontal eye-ﬁelds of the aging HIV brain. PLOS One 8 (6),
e66241 10.137/journal.pone.0066241] [Pubmed: 23840428].
Wilson, T.W., et al., 2013b. Functional brain abnormalities during ﬁnger-tapping in HIV-
infected older adults: a magnetoencephalography study. J. Neuroimmune Pharmacol.
8 (4), 965–974. http://dx.doi.org/10.1007/s11481-013-9477-123749418.
Wilson, T.W., et al., 2015. Multimodal neuroimaging evidence of alterations in cortical
structure and function in HIV-infected older adults. Hum. Brain Mapp. 36 (3),
897–910. http://dx.doi.org/10.1002/hbm.2267425376125.
Wohlschlaeger, J., et al., 2009.Whitematter changes in HIV-1 infected brains: A combined
gross anatomical and ultrastructural morphometric investigation of the corpus
callosum. Clin. Neurol. Neurosurg. 111 (5), 422–429. http://dx.doi.org/10.1016/j.
clineuro.2008.12.00619185416.
Wolff, S.D., Balaban, R.S., 1994. Magnetization transfer imaging: practical aspects and clin-
ical applications. Radiology 192 (3), 593–599. http://dx.doi.org/10.1148/radiology.
192.3.80589198058919.
Wu, Y., et al., 2006. Diffusion alterations in corpus callosum of patients with HIV. A.J.N.R.
Am. J. Neuroradiol. 27 (3), 656–66016552012.
Wu, Y., et al., 2008. Whole brain and localized magnetization transfer measurements are
associated with cognitive impairment in patients infected with human immunodeﬁ-
ciency virus. A.J.N.R. Am. J. Neuroradiol. 29 (1), 140–145. http://dx.doi.org/10.3174/
ajnr.A074017928382.
Yoshizawa, T., Motonishi, S., Saitoh, M., 2007. [Case of acute primary HIV infection with
menigoencephalitis demonstrating high signal intensity of the bilateral globus
pallidus in T2-weighted MRI]. Rinsho Shinkeigaku 47 (9), 597–60018018620.
